Management of Passive Anti-D Episode

Understanding Passive Anti-D Exposure

The American Society of Clinical Oncology recommends administering RhD immune globulin (RhIG) within 72 hours to prevent active alloimmunization in Rh-negative individuals exposed to RhD-positive blood products, prioritizing younger females of childbearing potential 1, 2, 3
Platelets themselves do not express RhD antigens, but platelet preparations contain sufficient contaminating RBCs to induce Rh sensitization even in immunosuppressed patients 1, 2, 3
The minimum RBC volume to elicit a primary anti-D immune response in RhD-negative recipients is only 0.03 mL, which falls within the RBC content range of many platelet products 4, 5
Modern apheresis platelet products contain approximately 0.00043 mL of RBCs, while whole-blood-derived products contain approximately 0.036 mL 4, 5

The American Society of Clinical Oncology prioritizes RhIG administration for RhD-negative children, particularly girls, and women of childbearing age 1, 2, 3, 6
Any RhD-negative patient with future transfusion needs where preventing alloimmunization is clinically important should also be prioritized 5

25 mg (125 IU) of anti-D immunoglobulin protects against 1 mL of RBCs (older guideline) 1, 2, 3, 6
20 mg (100 IU) of RhIG protects against 1 mL of RBCs (updated guideline) 4, 5
Estimate RBC contamination in the platelet unit (typically 0.00043-0.036 mL per unit) and administer a standard dose accordingly 4

Give RhIG before or immediately after the transfusion for maximum efficacy 3
Still effective if given within 72 hours of RhD-positive RBC exposure 1, 2, 3, 4, 5, 6

Identify the exposure: confirm RhD-negative recipient received RhD-positive or unknown phenotype platelets and document timing of transfusion 1, 2, 3
Assess patient priority: high priority for female children and women of childbearing age, moderate priority for other patients with future transfusion needs 1, 2, 3, 4, 5, 6
Calculate and administer dose: estimate RBC contamination or use standard dose and prefer IV route if patient is thrombocytopenic 1, 2, 3, 4, 5, 6

Fetal RBCs display RhD antigens from as early as 6 weeks gestation, making maternal sensitization possible even in early pregnancy 7
For bleeding events before 12 weeks: minimum 50 μg RhIG within 72 hours (or 300 μg if lower dose unavailable) 7
Prioritize pregnant patients at 28 weeks gestation for available RhIG doses during shortages 7